STAT3
STAT3 is a widely expressed STAT family transcription factor that regulates cellular growth, differentiation, survival, immunity, hematopoiesis, and cell migration[1]. Mechanistically, cytokines and growth factors activate JAKs, phosphorylate STAT proteins, promote STAT dimerization, and drive nuclear transcriptional regulation[2]. In inflammatory disease models, STAT3 shows strong tyrosine phosphorylation in human ulcerative colitis, Crohn’s disease, and DSS-induced mouse colitis, where IL-6 deficiency reduces colitis and STAT3 activation[3]. In cancer models, persistent STAT3 activation supports proliferation, survival, invasion, metastasis, immune evasion, and drug resistance, making STAT3 signaling a practical axis for tumor biology research[1][4]. Compared with related isoforms, STAT1 knockout mice mainly show impaired interferon signaling, while STAT3 is emphasized in IL-6-linked inflammation, tumor progression, and Th17-related immune dysfunction[2][5]. For experimental applications, JAK/STAT inhibitors such as AG490 and AZD1480 reduce STAT1/STAT3 activation in renal ischemia-reperfusion and α-synuclein neuroinflammation models[6][7].
References:
- [1]. Liu Y, et al. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. 2021 Feb;54(2):e12974. [Content Brief]
- [2]. Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):75-120. doi: 10.3109/10799899909036638. PMID: 10071751. et al. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):75-120. [Content Brief]
- [3]. Suzuki A, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med. 2001 Feb 19;193(4):471-81. [Content Brief]
- [4]. Wu CJ, et al. Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. Cancers (Basel). 2019 Dec 19;12(1):24. [Content Brief]
- [5]. Tolomeo M, et al. The STAT Signaling Pathway in HIV-1 Infection: Roles and Dysregulation. Int J Mol Sci. 2025 Sep 18;26(18):9123. [Content Brief]
- [6]. Si Y, et al. Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation. J Transl Med. 2013 Jun 9;11:141. [Content Brief]
- [7]. Qin H, et al. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. J Neurosci. 2016 May 4;36(18):5144-59. [Content Brief]
All Product Categories
-
STAT3 Inhibitors
(269)
View all products
-
STAT3 Agonist
(1)
View all products
-
STAT3 Antagonist
(1)
View all products
-
STAT3 Activators
(12)
View all products
-
STAT3 Modulators
(7)
View all products
-
STAT3 Inducer
(1)
View all products
-
STAT3 Degraders
(12)
View all products
-
STAT3 Ligands
(2)
View all products
-
STAT3 Related Products (320)
Related Products (320)
-
Antibodies (5)
-
DM243
0 ImagesCat. No.: HY-182273CAS No.: 3106606-59-8DM243 is an EPAC1 activator and STAT3 modulator with an pIC50 of 4.769 for EPAC1. DM243 increases GTP-bound Rap1 levels in EPAC1-expressing cells. DM243 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM243 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing α-smooth muscle actin and Collagen I levels in lung fibroblasts. DM243 exhibits minimal cytotoxicity in normal human lung fibroblasts.
-
L-Glutamine (GMP)
0 ImagesL-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
-
STAT3/NF-κB-IN-3
0 ImagesCat. No.: HY-184736STAT3/NF-κB-IN-3 is an orally active STAT3/NF-κB inhibitor with anti-inflammatory and antioxidant activities, which specifically blocks the phosphorylation of NF-κB and STAT3 proteins. STAT3/NF-κB-IN-3 downregulates the expression of iNOS and NOX-2 in macrophages, reduces intracellular levels of ROS and MDA, and upregulates the expression of antioxidant genes at the same time. In a mouse model of acute liver failure induced by LPS/D-GalN, STAT3/NF-κB-IN-3 alleviates liver necrosis and inflammatory cell infiltration, and reduces the release of pro-inflammatory cytokines such as IL-6 and IL-12 via the TLR4 pathway. STAT3/NF-κB-IN-3 can be used in studies related to acute liver failure.
-
ROCK2-IN-7
0 ImagesCat. No.: HY-149700CAS No.: 3000541-95-4ROCK2-IN-7 is a kinase inhibitor targeting to ROCK2. ROCK2-IN-7 inhibits ROCK2/pSTAT3 Signaling. ROCK2-IN-7 suppresses systemic immunity activation and attenuates inflammation in psoriasis model.
-
PHI-501
0 ImagesCat. No.: HY-153858CAS No.: 2470433-36-2PHI-501 is a dual inhibitor targeting RAF/DDR. PHI-501 exhibits significant anti-proliferative effects in melanoma cell lines and significantly inhibits the colony formation of drug-resistant cells. PHI-501 strongly inhibits ERK and AKT phosphorylation. PHI-501 downregulates the gene sets in drug-resistant cells of TNFA-NFKB, IL6-JAK-STAT3, and KRAS signaling pathways as well as the epithelial-mesenchymal transition (EMT) signaling pathways. PHI-501 demonstrates significant anti-tumor effects in the SK-MEL3DR xenograft model. PHI-501 can be used for research on the problem of drug resistance in melanoma.
-
EGFR kinase-IN-8
0 ImagesCat. No.: HY-180922CAS No.: 3081622-35-4EGFR kinase-IN-8 (Compound H8b) is an EGFR inhibitor. EGFR kinase-IN-8 potently inhibits both triple-mutated EGFRL858R/T790M/C797S (IC50 = 3.86 nM) and double-mutated EGFRL858R/T790M (IC50 = 1.23 nM). EGFR kinase-IN-8 suppresses EGFR phosphorylation and downstream AKT, STAT3, and MAPK signaling. EGFR kinase-IN-8 exhibits anticancer activity against non-small cell lung cancer.
-
SCP-7
0 ImagesCat. No.: HY-187792CAS No.: 2479389-64-3SCP-7 is a STAT3 inhibitor with a Kd value of 795 nM. SCP-7 induces mitochondrial dysfunction, increases ROS levels and promotes apoptosis. SCP-7 induces G2/M phase arrest of the cell cycle. SCP-7 inhibits the proliferation, migration and colony formation of colorectal cancer cells. SCP-7 suppresses tumor growth in a mouse xenograft model of colorectal cancer. SCP-7 is applicable to research related to colorectal cancer.
-
HSP110-IN-1
0 ImagesCat. No.: HY-184162CAS No.: 2991567-27-0HSP110-IN-1 is a HSP110 inhibitor. HSP110-IN-1 binds to HSP110, inhibits the activity of STAT3, and downregulates the expression of downstream genes VEGF, MMP7 and MMP9. HSP110-IN-1 abrogates IL-6-induced epithelial-mesenchymal transition and inhibits the proliferation of colorectal cancer cells. HSP110-IN-1 remodels the tumor microenvironment by inducing a pro-inflammatory phenotype, regulates macrophages, induces PD-L1 expression, and enhances anti-PD-L1 antibody-mediated tumor regression. HSP110-IN-1 can be used in studies related to colorectal cancer.
-
Anti-inflammatory agent 92
0 ImagesCat. No.: HY-159157CAS No.: 1609387-77-0Anti-inflammatory agent 92 (compound LD4) is a porphyrin derivative. Anti-inflammatory agent 92 has anti-inflammatory properties. Anti-inflammatory agent 92 can alleviate ulcerative colitis by inhibiting the STAT3-EPHX2 axis.
-
ODZ10117
0 ImagesCat. No.: HY-182380CAS No.: 1632152-27-2ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC50 of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease.
-
(trans)-STAT6-IN-13
0 ImagesCat. No.: HY-164216A
-
Golotimod TFA
0 ImagesCat. No.: HY-14743ACAS No.: 2828433-07-2Synonyms: SCV 07 TFA; Gamma-D-glutamyl-L-tryptophan TFAGolotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
-
YZZ-24
0 ImagesCat. No.: HY-184419YZZ-24 is a highly potent and selective STAT3 inhibitor featuring a Ki of 0.26 μM. YZZ-24 directly binds to STAT3 (STAT3 SH2 domain) and effectively inhibits STAT3 phosphorylation at tyrosine 705 (p-STAT3Tyr705) and STAT3 phosphorylation at serine 727 (p-STAT3Ser727), thereby blocking downstream oncogenic signaling and inducing apoptosis, while having minimal impact on upstream kinases. YZZ-24 can be used in colorectal cancer research.
-
HJC0416
0 ImagesCat. No.: HY-12352CAS No.: 1617518-22-5
-
TU-100
0 ImagesCat. No.: HY-165386CAS No.: 1310907-71-1TU-100 is a Japanese herbal medicine. TU-100 exhibits anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. TU-100 can antagonize the M2 polarization phenotype of macrophages in the tumor microenvironment by suppressing the TLR4/NF-κB/STAT3 axis. TU-100 can inhibit the high expression of MMP-2, COX-2, and VEGF in TAMs.
-
JAK2-IN-13
0 ImagesCat. No.: HY-174988JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms.
-
STAT3-IN-46
0 ImagesCat. No.: HY-175771STAT3-IN-46 is a selective and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3) (KD = 323.3 nM). STAT3-IN-46 directly binds to the SH2 domain of the STAT3 and inhibits IL-6/JAK/STAT3 signaling pathway (IC50 = 0.87 μM) and downregulates c-Myc and Bcl-2 levels. STAT3-IN-46 can be used for the research of cancer, such as triple-negative breast cancer.
